Psoriatic Arthritis Breakfast Briefings from #ACR2020

Psoriatic Arthritis Breakfast Briefing – Day 6

November 11, 2020
Abstract Number: 0336
Gossec L, Walsh J, Michau K, et al.
Anxiety and Depression in Psoriatic Arthritis (PsA) – Prevalence and Impact on Patient Reported Outcomes: Real-World Survey in the US and Europe

Psoriatic Arthritis Breakfast Briefing – Day 5

November 10, 2020
Abstract Number: 0329
Ogdie A, Hwang M, Veeranki P, et al.
Healthcare Utilization and Costs Associated with Functional Status in Patients with Psoriatic Arthritis

Psoriatic Arthritis Breakfast Briefing – Day 4

November 9, 2020
Abstract Number: L03
Mease P, Deodhar A, van der Heijde D, et al.
Efficacy and Safety of Deucravacitinib (BMS-986165), an Oral, Selective Tyrosine Kinase 2 Inhibitor, in Patients with Active Psoriatic Arthritis: 
Results from a Phase 2, Randomized, Double-Blind, Placebo-Controlled Trial 

Psoriatic Arthritis Breakfast Briefing – Day 3

November 8, 2020
Abstract Number: 0619
Sharma N, Girardi N, Wong K

Pharmacist Intervention: Reducing Insurance Denials of Specialty Medications

Psoriatic Arthritis Breakfast Briefing – Day 2

November 7, 2020
Abstract Number: 0308
Karmacharya P, Wright K, Achenbach S J, et al.
Delay in Transition from Psoriasis to Psoriatic Arthritis: A Population Based Study
_________________________________________________________________________
Abstract Number: 0309
Karmacharya P, Wright K, Achenbach S J, et al.
Diagnostic Delay in Psoriatic Arthritis: A Population Based Study

Psoriatic Arthritis Breakfast Briefing – Day 1

November 6, 2020
Abstract Number: 0320
Gazitt T, Elhija MA, Haddad A, et al.

Assessment of Implementation of Treat to Target Concept Using Validated Composite Scores in Psoriatic Arthritis Patients